Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

Vladimir Coric; Christopher H. van Dyck; Stephen Salloway; Niels Andreasen; Mark Brody; Ralph Richter; Hilkka Soininen; Stephen Thein; Thomas Shiovitz; Gary D. Pilcher; Susan Colby; Linda Rollin; Randy Dockens; Chahin Pachaï; Erik Portelius; Ulf Andréasson; Kaj Blennow; Holly Soares; Charles F. Albright; Howard Feldman; Robert Berman

doi:10.1001/archneurol.2012.2194

Abstract

clinicaltrials.gov Identifier: NCT00810147

Keywords

TolerabilityDiscontinuationMedicinePlaceboAdverse effectInternal medicineGastroenterologyPharmacodynamicsPharmacologyPharmacokineticsPathology

MeSH Terms

Activities of Daily LivingAgedAged80 and overAlzheimer DiseaseAmyloid Precursor Protein SecretasesAmyloid beta-PeptidesBody WeightDose-Response RelationshipDrugDouble-Blind MethodEnzyme InhibitorsFemaleHumansImmunoprecipitationInternational CooperationMagnetic Resonance ImagingMaleMass SpectrometryMiddle AgedNeuropsychological TestsOutcome AssessmentHealth CareOxadiazolesPsychiatric Status Rating ScalesSulfonamidesTime Factorstau Proteins

Affiliated Institutions

Bristol-Myers Squibb (United States) US

Related Publications

Donanemab in Early Symptomatic Alzheimer Disease

John R. Sims , Jennifer A. Zimmer , Cynthia Evans +97 more

Importance There are limited efficacious treatments for Alzheimer disease. Objective To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyl...

2023 JAMA 1935 citations

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

Rita Nanda , Laura Q.M. Chow , Elizabeth Claire Dees +9 more

Purpose Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negativ...

2016 Journal of Clinical Oncology 1427 citations

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Julie R. Brahmer , Charles G. Drake , Ira Wollner +17 more

Purpose Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and ...

2010 Journal of Clinical Oncology 2881 citations

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn , Masafumi Ikeda , Andrew X. Zhu +17 more

PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death r...

2020 Journal of Clinical Oncology 1120 citations

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

Yelena Y. Janjigian , Kohei Shitara , Markus Moehler +26 more

First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median ov...

2021 The Lancet 2580 citations

Publication Info

Year: 2012
Type: article
Volume: 69
Issue: 11
Pages: 1430-1430
Citations: 359
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

359

OpenAlex

Influential

325

CrossRef

Cite This

APA Style

                            
                                
                                    Vladimir Coric, 
                                
                                    Christopher H. van Dyck, 
                                
                                    Stephen Salloway
                                
                                et al.
                            
                            (2012). 
                            Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease. 
                            Archives of Neurology
                            , 69
                            (11)
                            , 1430-1430.
                            https://doi.org/10.1001/archneurol.2012.2194
                        

Identifiers

DOI: 10.1001/archneurol.2012.2194
PMID: 22892585

Data Quality

Data completeness: 86%